Mackenzie Financial Corp Lineage Cell Therapeutics, Inc. Transaction History
Mackenzie Financial Corp
- $71.6 Billion
- Q2 2025
A detailed history of Mackenzie Financial Corp transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 11,404 shares of LCTX stock, worth $19,158. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,404Holding current value
$19,158% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
137Shares Held
99.6MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$83.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$16.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$14.3 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.06 Million6.02% of portfolio
-
Comerica Bank4.6MShares$7.73 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $285M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...